Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study
Clinical trial NCT07709624 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07709624
- Sponsor
- TTY Biopharm
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-12-01
- Primary completion
- 2030-01-28
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.